Singapore markets open in 8 hours 9 minutes

Repare Therapeutics Inc. (RPTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
16.20-0.07 (-0.43%)
As of 11:36AM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 726.77M
Enterprise value 362.31M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)5.91
Price/book (mrq)2.26
Enterprise value/revenue 3.01
Enterprise value/EBITDA -13.42

Trading information

Stock price history

Beta (5Y monthly) 0.06
52-week change 3-28.36%
S&P500 52-week change 3-16.16%
52-week high 323.83
52-week low 38.06
50-day moving average 314.67
200-day moving average 313.17

Share statistics

Avg vol (3-month) 3137.08k
Avg vol (10-day) 3155.52k
Shares outstanding 541.96M
Implied shares outstanding 6N/A
Float 815.34M
% held by insiders 15.76%
% held by institutions 185.94%
Shares short (14 Nov 2022) 41.56M
Short ratio (14 Nov 2022) 410.01
Short % of float (14 Nov 2022) 45.93%
Short % of shares outstanding (14 Nov 2022) 43.71%
Shares short (prior month 13 Oct 2022) 41.58M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin -21.31%
Operating margin (ttm)-23.98%

Management effectiveness

Return on assets (ttm)-5.12%
Return on equity (ttm)-9.80%

Income statement

Revenue (ttm)120.51M
Revenue per share (ttm)2.91
Quarterly revenue growth (yoy)40,383.80%
Gross profit (ttm)-80.25M
EBITDA -27.01M
Net income avi to common (ttm)-25.68M
Diluted EPS (ttm)-3.08
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)370.35M
Total cash per share (mrq)8.83
Total debt (mrq)5.89M
Total debt/equity (mrq)1.93
Current ratio (mrq)6.31
Book value per share (mrq)7.29

Cash flow statement

Operating cash flow (ttm)9.22M
Levered free cash flow (ttm)29.53M